Yüklüyor......
Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H(1)-antihistamines. Omalizumab is a humanized monoclonal anti-IgE antibody that binds with free IgE antibodies and reduces the circulating levels of fre...
Kaydedildi:
| Yayımlandı: | Indian Dermatol Online J |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Medknow Publications & Media Pvt Ltd
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4763587/ https://ncbi.nlm.nih.gov/pubmed/26955580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2229-5178.174314 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|